Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-DCFBC
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**18F-DCFBC** is a low-molecular-weight radiopharmaceutical used as a positron emission tomography (PET) imaging agent. It specifically targets the prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer cells and associated with higher tumor grade and aggressive disease. Upon intravenous administration, 18F-DCFBC binds to PSMA-expressing tumor cells, allowing for their visualization using PET/CT imaging. This agent has been investigated primarily for the detection and characterization of primary and metastatic prostate cancer, showing high specificity for clinically significant high-grade lesions. The compound consists of a PSMA-targeted ligand labeled with the positron-emitting isotope fluorine F 18[2][4][5].
- Other names
- N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]-fluorobenzyl-L-cysteine
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 18F-DCFBC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-DCFBC.